XGEVA, also known by its generic name denosumab, is a prescription medication used primarily in the management of bone-related conditions associated with various cancers. It is specifically designed to prevent bone fractures, reduce bone pain, and manage bone loss in patients with metastatic cancers that have spread to the bone, such as breast and prostate cancer, as well as in cases of multiple myeloma. XGEVA works by targeting and inhibiting a protein involved in bone resorption called RANK ligand, which plays a key role in the process of bone breakdown. By blocking this protein, XGEVA helps to strengthen bones, making them less susceptible to fractures and other complications. It is administered through subcutaneous injections and is often part of a comprehensive treatment plan for patients dealing with the challenges of cancer-induced bone conditions.